Voyager Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
VYGR$1.83-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(amounts in thousands, except share and per share data)
| | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended · · Nine Months Ended · | |||||||||||||
| · · September 30, · September 30, | |||||||||||||
| · 2025 · 2024 · 2025 · 2024 | |||||||||||||
| Collaboration revenue (including from related parties, see note 12) | | $13,365 | $24,629 | | $25,038 | $73,723 | | ||||||
| Operating expenses: | | | | | | | | | | | | | |
| Research and development | | | 35,866 | | 30,241 | | 98,722 | | 91,785 | | |||
| General and administrative | | | 8,093 | | 8,168 | | 28,228 | | 26,926 | | |||
| Total operating expenses | | | 43,959 | | | 38,409 | | 126,950 | | | 118,711 | | |
| Operating loss | | | (30,594) | | | (13,780) | | | (101,912) | | | (44,988) | |
| Other income, net: | | | | | | | | | | | | | |
| Interest income | | | 2,385 | | 4,579 | | 8,507 | | 14,334 | | |||
| Other income | | | 400 | | 200 | | 1,245 | | 220 | | |||
| Total other income, net | | | 2,785 | | 4,779 | | 9,752 | | 14,554 | | |||
| Loss before income taxes | | | (27,809) | | | (9,001) | | | (92,160) | | | (30,434) | |
| Income tax provision | | | 83 | | | 43 | | | 135 | | | 81 | |
| Net loss | | $(27,892) | | $(9,044) | | $(92,295) | | $(30,515) | | ||||
| Other comprehensive income: | | | | | | | | | | | | | |
| Net unrealized gain on available-for-sale securities | | 228 | | 489 | | 414 | | 15 | | ||||
| Total other comprehensive income | | 228 | | 489 | | 414 | | 15 | | ||||
| Comprehensive loss | | $(27,664) | | $(8,555) | | $(91,881) | | $(30,500) | | ||||
| | | | | | | | | | | | | | |
| Net loss per share, basic and diluted | | $(0.47) | | $(0.16) | | $(1.57) | | $(0.53) | | ||||
| | | | | | | | | | | | | | |
| Weighted-average common shares outstanding, basic and diluted | | | 58,803,015 | | | 57,851,110 | | | 58,608,075 | | | 57,564,413 | |
| | | | | | | | | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.